O. Golubtsova

Efficacy and safety of switching within one international non-proprietary name (elexacaftor/tezacaftor/ivacaftor) in children with cystic fibrosis: clinical experience of transition from Trikafta to Trilexa

Cystic fibrosis is caused by mutations in the cystic fibrosis transmembrane regulator gene and is accompanied by chronic damage to the respiratory and gastrointestinal systems. Triple therapy with elexacaftor, tezacaftor, and ivacaftor significantly improves lung function and nutritional status. However, the high cos...